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ABSTRACT  
We present the case of a 55 year old patient under immunosuppressive treatment 
who developed multiple anogenital condylomata acuminata. Urethroscopy showed 
extensive condylomatous involvement of the entire penile urethra. Due to the 
potential morbidity of any surgical approach, we opted for an experimental 
treatment with Imiquimod (250 mg 5%-Imiquimod intraurethrally 3 times weekly), 
which was well tolerated. After a remarkable initial response and a continuous 
decline in the number of lesions, only minimal residual condylomata were left after 
15 months. These were resected with the Holmium:YAG laser. Follow-up 
urethroscopy at three months showed no recurrence or signs of urethral stricture.  
 
CASE REPORT  
A 55 year old patient who was treated with Rituximab for a nodal marginal zone B-
cell lymphoma developed multiple anogenital condylomata acuminata under this 
immunosuppressive therapy. After successful therapy of the external condylomata 
with topical Imiquimod and cryotherapy, the patient was referred to our urologic 
clinic with the suspicion of intraurethral condylomata. The patient reported 
infrequent observation of blood at the urethral meatus, but an otherwise unimpaired 
micturition. Subsequent urethroscopy showed extensive circumferential 
involvement of the entire penile urethra with condylomata acuminata (Fig. 1). 
Because of the extent of the lesions and the respective conceivable morbidity of a 
surgical therapy (e.g. strictures, postoperative sclerosis and scars of the adjacent 
corpora cavernosa), we suggested to treat the lesions with urethral application of 
Imiquimod (IQ) 5%. The patient was instructed to apply 250 mg 5% Imiquimod 
with an insulin syringe into the urethra three times per week every other week. No 
urethral occlusion (i.e. penis-clamp) was used, however the patient self-
administered the Imiquimod immediately after the last micturition before going to 
bed at night. Four weeks later, the first follow-up urethroscopy showed a 
significant reduction of the lesions. Apart from infrequent mild dysuria and 
occasional minimal blood at the meatus the patient tolerated the treatment very well 
and continued the application of Imiquimod three times weekly every week. 
Urethroscopies six weeks (Fig. 2), 12 weeks, 18 weeks (Fig. 3A) and 9 months 
(Fig. 3B) later showed a continuous significant reduction of the lesions. After 12 
months, the patient reduced the application frequency to twice weekly due to 
burning sensation in the urethra. After 14 months, there were only minimal residual 
condylomatas seen in the distal part of the urethra and we decided to treat those 
lesions with the Ho:YAG laser. To enhance the therapeutic effectiveness, adjuvant 
treatment with Imiquimod 5% was continued for three months. Follow-up 
urethroscopy at three months showed no recurrence or signs of urethral stricture 
(Fig. 4).  
 
DISCUSSION  
Condylomata acuminata are among the most common sexually transmitted 
diseases. The main risk factors appear to be young age, sexual promiscuity, 
intercourse with a partner with HPV disease and deficient immune response.[1] 
The urethra is involved in up to 30% of male patients. Oriel et al. reported up to 
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90% of urethral condylomata to be located at the meatus.[2] The comparatively rare 
proximal involvement of the urethra causes problems in diagnosis and may lead to 
recurrent autoinfection or reinfection. Many specialists consider laser therapy as the 
treatment of choice for urethral condylomata. However, there are some 
considerable side effects to this approach (e.g. strictures). McKenna and coworkers 
suggested the Nd:YAG laser as the treatment of choice because of its universal 
applicability for tissue coagulation of the external genitals and in endoscopic use, 
as well as the ability to control its power-dependent depth of penetration of several 
millimeters.[3] However, the holmium:YAG laser might be an alternative to the 
Nd:YAG laser in the treatment of urethral condylomas and may cause less scarring. 
Other treatment options include 5- Fluorouracil (5-FU) treatment[4], interferon-
alpha 2a[5], carbon dioxide laser[6], and cryotherapy.[7] Imiquimod (IQ) is a 
member of a class of immune-response modifying agents. It is a synthetic 
imidazoquinoline amine that enhances, through cytokine induction, both the innate 
and acquired immune pathways, resulting in immunomodulating, antiviral and 
antitumor effects.[8] The effect of IQ cream on immunity has suggested its possible 
use in the treatment of a wide variety of dermatologic conditions in which the 
immune system is thought to play a role in regression of the disease.[9] IQ is an 
effective topical treatment for external genital and perianal warts and has received 
the respective FDA approval in 1997. During topical IQ treatment it is common for 
patients to experience inflammatory local skin reactions that range from mild to 
severe, and may extend beyond the application site onto the surrounding 
environment. To the best of our knowledge, there are no reports in the literature 
about the intraurethral application of Imiquimod 5% for the treatment of 
condylomata acuminata. Our case demonstrates that IQ can be an effective 
treatment option for extensive urethral condylomata. The primary advantage of this 
treatment is the potentialy reduction in morbidity compared to surgical therapies. 
Treatment duration, however, is long in our case. It took more than one year of 
intraurethral IQ applications to reduce the urethral condylomata to a minimum. 
Moreover, the recurrence of urethral condylomata after surgical removal, which is 
more frequent than the respective recurrence of external genital warts, can pose a 
therapeutic challenge.[3] This is partly because epithelia of healthy appearance at 
the time of treatment may already have latent HPV infection, and HPV 
efflorescences may only form at a later time. As in our case, IQ could be used as a 
neoadjuvant and/or as an adjuvant treatment in combination with standard laser 
therapy of the urethra to optimize the therapeutic efficacy. Based on our experience 
we believe that IQ and newer generations of imidazoquinolines (e.g. resiquimod) 
deserve further investigation regarding their potential role in the treatment of 
intraurethral condylomata acuminata.  
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